Skip Navigation LinksHome > September 2008 - Volume 51 - Issue 3 > Postmenopausal Hormone Therapy and Cardiovascular Disease in...
Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e318181de86
Evidence-Based Approach to Menopause

Postmenopausal Hormone Therapy and Cardiovascular Disease in Perspective

Hodis, Howard N. MD* †; Mack, Wendy J. PhD† ‡

Collapse Box


The totality of data indicate that the window of opportunity for reducing mortality and coronary heart disease is initiation of hormone therapy (HT) within 6 years of menopause and/or by 60 years of age and continued for 6 years or more. Additionally, the risks of HT are rare (<1/1000) especially in younger postmenopausal women and comparable with other primary prevention therapies. In fact, as randomized controlled trial results accumulate, the more they look like the consistent observational data. These studies showed that young postmenopausal women with menopausal symptoms who use HT for long periods of time have lower rates of mortality and coronary heart disease than comparable postmenopausal women who do not use HT.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.